Literature DB >> 34617445

Dexamethasone Transiently Enhances Transgene Expression in the Liver When Administered at Late-Phase Post Long-Term Adeno-Associated Virus Transduction.

Zheng Chai1, Xintao Zhang1, Amanda Lee Dobbins1, Richard Jude Samulski1,2, Elizabeth P Merricks3,4, Timothy C Nichols3,4, Chengwen Li1,5,6.   

Abstract

Glucocorticoids have anti-inflammatory and immunosuppressive functions and have commonly been used for preventing liver toxicity after the systemic application of a high dose of adeno-associated virus (AAV) vector for gene therapy. Clinical studies have reported that glucocorticoids have rescued factor IX (FIX) expression in patients with hemophilia B who showed a reduced FIX expression at 6 to 10 weeks post-AAV vector administration. In this study, we explored whether glucocorticoids could affect transgene expression in AAV targeted livers in animal models. When dexamethasone was applied before AAV9/FIX vector administration in the wild-type C57BL/6 mice, FIX expression was much higher than that of the control mice at any time point. More importantly, FIX expression transiently increased after dexamethasone was administered at week 6 or later post-AAV injection regardless of the various dexamethasone treatments applied. The transient enhancement in transgene expression was observed once there were one to several consecutive dexamethasone treatments completed. A similar result was also achieved in other wild-type BALB/c and hemophilia B mice that were treated with AAV9/FIX and dexamethasone. This mechanism study demonstrated that the administration of dexamethasone did not change either AAV genome copy number or transgene expression at the transcription level but transiently decreased interferon beta (IFN-β) and tumor necrosis factor alpha (TNF-α) expression in the livers of mice at a later time after AAV injection. Next, we studied the effect of dexamethasone on late transgene expression in hemophilia B dogs. Dexamethasone was administered 1 year after AAV9/FIX injection. Inconsistent with the results in mice, no significant change of FIX expression was observed in hemophilia B dogs. In summary, the results from this study indicate that dexamethasone may have various effects on transgene expression in AAV-transduced livers in different species, which provides valuable information about the rational application of dexamethasone in future clinical studies.

Entities:  

Keywords:  adeno-associated virus; glucocorticoid; liver transduction

Mesh:

Substances:

Year:  2022        PMID: 34617445      PMCID: PMC8885437          DOI: 10.1089/hum.2021.083

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   4.793


  43 in total

1.  Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.

Authors:  Zheng Chai; Junjiang Sun; Kelly Michelle Rigsbee; Mei Wang; R Jude Samulski; Chengwen Li
Journal:  J Control Release       Date:  2017-08-05       Impact factor: 9.776

Review 2.  Role of GILZ in immune regulation, glucocorticoid actions and rheumatoid arthritis.

Authors:  Elaine Beaulieu; Eric F Morand
Journal:  Nat Rev Rheumatol       Date:  2011-05-10       Impact factor: 20.543

Review 3.  Adeno-associated viral vectors for the treatment of hemophilia.

Authors:  Katherine A High; Xavier M Anguela
Journal:  Hum Mol Genet       Date:  2015-11-27       Impact factor: 6.150

4.  Across-species meta-analysis of dexamethasone pharmacokinetics utilizing allometric and scaling modeling approaches.

Authors:  Dawei Song; William J Jusko
Journal:  Biopharm Drug Dispos       Date:  2021-03-17       Impact factor: 1.627

5.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.

Authors:  Amit C Nathwani; Edward G D Tuddenham; Savita Rangarajan; Cecilia Rosales; Jenny McIntosh; David C Linch; Pratima Chowdary; Anne Riddell; Arnulfo Jaquilmac Pie; Chris Harrington; James O'Beirne; Keith Smith; John Pasi; Bertil Glader; Pradip Rustagi; Catherine Y C Ng; Mark A Kay; Junfang Zhou; Yunyu Spence; Christopher L Morton; James Allay; John Coleman; Susan Sleep; John M Cunningham; Deokumar Srivastava; Etiena Basner-Tschakarjan; Federico Mingozzi; Katherine A High; John T Gray; Ulrike M Reiss; Arthur W Nienhuis; Andrew M Davidoff
Journal:  N Engl J Med       Date:  2011-12-10       Impact factor: 176.079

6.  Long-term safety and efficacy of factor IX gene therapy in hemophilia B.

Authors:  Amit C Nathwani; Ulreke M Reiss; Edward G D Tuddenham; Cecilia Rosales; Pratima Chowdary; Jenny McIntosh; Marco Della Peruta; Elsa Lheriteau; Nishal Patel; Deepak Raj; Anne Riddell; Jun Pie; Savita Rangarajan; David Bevan; Michael Recht; Yu-Min Shen; Kathleen G Halka; Etiena Basner-Tschakarjan; Federico Mingozzi; Katherine A High; James Allay; Mark A Kay; Catherine Y C Ng; Junfang Zhou; Maria Cancio; Christopher L Morton; John T Gray; Deokumar Srivastava; Arthur W Nienhuis; Andrew M Davidoff
Journal:  N Engl J Med       Date:  2014-11-20       Impact factor: 176.079

7.  Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A.

Authors:  Lily M Du; Paquita Nurden; Alan T Nurden; Timothy C Nichols; Dwight A Bellinger; Eric S Jensen; Sandra L Haberichter; Elizabeth Merricks; Robin A Raymer; Juan Fang; Sevasti B Koukouritaki; Paula M Jacobi; Troy B Hawkins; Kenneth Cornetta; Qizhen Shi; David A Wilcox
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 8.  Engineering adeno-associated virus vectors for gene therapy.

Authors:  Chengwen Li; R Jude Samulski
Journal:  Nat Rev Genet       Date:  2020-02-10       Impact factor: 59.581

Review 9.  Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects.

Authors:  Julien Baruteau; Simon N Waddington; Ian E Alexander; Paul Gissen
Journal:  J Inherit Metab Dis       Date:  2017-05-31       Impact factor: 4.982

Review 10.  Clinical Considerations for Capsid Choice in the Development of Liver-Targeted AAV-Based Gene Transfer.

Authors:  Steven Pipe; Frank W G Leebeek; Valerie Ferreira; Eileen K Sawyer; John Pasi
Journal:  Mol Ther Methods Clin Dev       Date:  2019-09-10       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.